Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study.
Chemotherapy
Cochlea
Craniospinal irradiation
Pediatric cancer
Radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
17
03
2024
accepted:
11
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
This study aimed to analyze treatment-related risk factors for sensorineural hearing loss (SNHL) and an indication for hearing aids (IHA) in medulloblastoma patients after craniospinal radiotherapy (CSRT) and platin-based chemotherapy (PCth). A total of 58 patients (116 ears) with medulloblastoma and clinically non-relevant pre-treatment hearing thresholds were included. Cranial radiotherapy and PCth were applied sequentially according to the HIT 2000 study protocol or post-study recommendations, the NOA-07 protocol, or the PNET (primitive neuroectodermal tumor) 5 MB therapy protocol. Audiological outcomes up to a maximum post-therapeutic follow-up of 4 years were assessed. The incidence, post-treatment progression, and time-to-onset of SNHL, defined as Muenster classification grade ≥MS2b, were evaluated. Risk factors for IHA were analyzed separately. While 39 patients received conventionally fractionated RT (CFRT; group 1), 19 patients received hyperfractionated RT (HFRT; group 2). Over a median follow-up of 40 months, 69.2% of ears in group 1 experienced SNHL ≥MS2b compared to 89.5% in group 2 (p = 0.017). In multivariable Cox regressions analysis, younger age and increased mean cochlear radiation dose calculated as the equivalent dose in 2‑Gy fractions (EQD2) were associated with time-to-onset of SNHL ≥MS2b (p = 0.019 and p = 0.023, respectively) and IHA (p < 0.001 and p = 0.016, respectively). Tomotherapy and supine positioning were associated with a lower risk for IHA in univariable modelling only (p = 0.048 and p = 0.027, respectively). Young age and cochlear EQD2 D
Identifiants
pubmed: 39455453
doi: 10.1007/s00066-024-02308-5
pii: 10.1007/s00066-024-02308-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Kortmann RD, Kühl J, Timmermann B, Calaminus G, Dieckmann K, Wurm R, Sörensen N, Urban C, Gö bel U, Bamberg M (2001) Actual and future strategies in interdisciplinary treatment of medulloblastomas, supratentorial PNET and intracranial germ cell tumors in childhood. Strahlenther Onkol 177:447–461. https://doi.org/10.1007/pl00002426
doi: 10.1007/pl00002426
pubmed: 11591018
Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A (2008) Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 70:782–787. https://doi.org/10.1016/j.ijrobp.2007.07.2342
doi: 10.1016/j.ijrobp.2007.07.2342
pubmed: 17892918
Paulino AC, Lobo M, Teh BS, Okcu MF, South M, Butler EB, Su J, Chintagumpala M (2010) Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys 78:1445–1450. https://doi.org/10.1016/j.ijrobp.2009.09.031
doi: 10.1016/j.ijrobp.2009.09.031
pubmed: 20231075
Scobioala S, Parfitt R, Matulat P, Kittel C, Ebrahimi F, Wolters H, Zehnhoff-Dinnesen AA, Eich HT (2017) Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing: retrospective analysis of 29 medulloblastoma patients. Strahlenther Onkol 193:910–920. https://doi.org/10.1007/s00066-017-1205-y
doi: 10.1007/s00066-017-1205-y
pubmed: 28887665
Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, Von Hoff K, Faldum A, Mosseri V, Kortmann R (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30:3187–3193. https://doi.org/10.1200/JCO.2011.39.8719
doi: 10.1200/JCO.2011.39.8719
pubmed: 22851561
Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, Meyer WH (1989) Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7:754–760. https://doi.org/10.1200/JCO.1989.7.6.754
doi: 10.1200/JCO.1989.7.6.754
pubmed: 2715805
Wong KL, Song TT, Wee J, Fook-Chong SMC, De YW (2006) Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 24:1904–1909. https://doi.org/10.1200/JCO.2005.05.0096
doi: 10.1200/JCO.2005.05.0096
Chen WC, Jackson A, Budnick AS, Pfister DG, Kraus DH, Hunt MA, Stambuk H, Levegrun S, Wolden SL (2006) Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 106:820–829. https://doi.org/10.1002/cncr.21683
doi: 10.1002/cncr.21683
pubmed: 16421885
Scobioala S, Parfitt R, Matulat P, Byrne J, Langer T, Troschel FM, Hesping AE, Clemens E, Kaatsch P, Grabow D, Kaiser M, Spix C, Kremer LC, Calaminus G, Baust K, Kuehni CE, Weiss A, Strebel S, Kuonen R, Elsner S, Haupt R, Garré M, Gruhn B, Kepak T, Kepakova K, Winther JF, Kenborg L, Rechnitzer C, Hasle H, Kruseova J, Luks A, Lackner H, Bielack S, Beck J, Jürgens H, van den Heuvel-Eibrink MM, Zolk O, Eich HT, am Zehnhoff-Dinnesen A (2023) The impact of the temporal sequence of cranial radiotherapy and platin-based chemotherapy on hearing impairment in pediatric and adolescent CNS and head-and-neck cancer patients: a report from the pancareLIFE consortium. Int J Cancer. https://doi.org/10.1002/ijc.34732
doi: 10.1002/ijc.34732
pubmed: 37715472
Kinclová I, Hajtmanová E, Matula P, Balentová S, Muríň P, Ďuroška M, Kozlíková K (2020) Model-based calculation of thyroid gland normal tissue complication probability in head and neck cancer patients after radiation therapy. Strahlenther Onkol 196:561–568. https://doi.org/10.1007/s00066-020-01579-y
doi: 10.1007/s00066-020-01579-y
pubmed: 32016495
Beddok A, Maynadier X, Krhili S, Ala Eddine C, Champion L, Chilles A, Goudjil F, Zefkili S, Amessis M, Choussy O, Le Tourneau C, Buvat I, Créhange G, Carton M, Calugaru V (2023) Predictors of toxicity after curative reirradiation with intensity modulated radiotherapy or proton therapy for recurrent head and neck carcinoma: new dose constraints for pharyngeal constrictors muscles and oral cavity. Strahlenther Onkol 199:901–909. https://doi.org/10.1007/s00066-023-02080-y
doi: 10.1007/s00066-023-02080-y
pubmed: 37256301
Pepper NB, Stummer W, Eich HT (2022) The use of radiosensitizing agents in the therapy of glioblastoma multiforme—a comprehensive review. Strahlentherapie Onkol 198:507–526
doi: 10.1007/s00066-022-01942-1
Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM (2007) Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 67:469–479. https://doi.org/10.1016/j.ijrobp.2006.09.017
doi: 10.1016/j.ijrobp.2006.09.017
pubmed: 17236969
Hua C, Bass JK, Khan R, Kun LE, Merchant TE (2008) Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys 72:892–899. https://doi.org/10.1016/j.ijrobp.2008.01.050
doi: 10.1016/j.ijrobp.2008.01.050
pubmed: 18395355
Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P, Mendenhall WM (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2009.04.096
doi: 10.1016/j.ijrobp.2009.04.096
pubmed: 20171518
pmcid: 3319461
Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH, Butler EB, Woo SY (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52:599–605. https://doi.org/10.1016/S0360-3016(01)02641-4
doi: 10.1016/S0360-3016(01)02641-4
pubmed: 11849779
Knight KRG, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596. https://doi.org/10.1200/JCO.2004.00.5355
doi: 10.1200/JCO.2004.00.5355
pubmed: 16314621
Skinner R, Pearson ADJ, Amineddine HA, Mathias DB, Craft AW (1990) Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 61:927–931. https://doi.org/10.1038/bjc.1990.208
doi: 10.1038/bjc.1990.208
pubmed: 2372498
pmcid: 1971678
Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O (2004) Platinum compound-related ototoxicity in children. J Pediatr Hematol Oncol 26:649–655. https://doi.org/10.1097/01.mph.0000141348.62532.73
doi: 10.1097/01.mph.0000141348.62532.73
pubmed: 27811606
Bass JK, Hua CH, Huang J, Onar-Thomas A, Ness KK, Jones S, White S, Bhagat SP, Chang KW, Merchant TE (2016) Hearing loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol 34:1248–1255. https://doi.org/10.1200/JCO.2015.63.6738
doi: 10.1200/JCO.2015.63.6738
pubmed: 26811531
pmcid: 4933129
Rutkowsi S, Dobke J HIT 2000. https://www.gpoh.de/kinderkrebsinfo/content/fachinformationen/studienportal/abgeschlossene_studien_register/hit_2000_und_hit_2000_interim/index_ger.html . Accessed 3 Sept 2024
Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Di Kortmann R, Bogdahn U, Hau P (2018) Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol 20:400–410. https://doi.org/10.1093/neuonc/nox155
doi: 10.1093/neuonc/nox155
pubmed: 29016837
Dobke J SIOP PNET 5 MB. https://www.gpoh.de/kinderkrebsinfo/content/fachinformationen/studienportal/onkologische_studien_und_register/siop_pnet_5_mb/index_ger.html . Accessed 3 Sept 2024
Mynarek M, Milde T, Padovani L, Janssens GO, Kwiecien R, Mosseri V, Clifford SC, Doz F, Rutkowski S (2021) SIOP PNET5 MB trial: history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma. Cancers. https://doi.org/10.3390/cancers13236077
doi: 10.3390/cancers13236077
pubmed: 34885186
pmcid: 8657236
Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG (2007) Die „Münsteraner klassifikation“. eine neue einteilung der hochtonschwerhörigkeit nach cisplatingabe. HNO 55:299–306. https://doi.org/10.1007/s00106-005-1368-1
doi: 10.1007/s00106-005-1368-1
pubmed: 16437215
World Health Organization (2021) World report on hearing
Monson BB, Hunter EJ, Lotto AJ, Story BH (2014) The perceptual significance of high-frequency energy in the human voice. Front Psychol 5:1–11. https://doi.org/10.3389/fpsyg.2014.00587
doi: 10.3389/fpsyg.2014.00587
Moore BCJ (2016) A review of the perceptual effects of hearing loss for frequencies above 3 kHz. Int J Audiol 55:707–714. https://doi.org/10.1080/14992027.2016.1204565
doi: 10.1080/14992027.2016.1204565
pubmed: 27414746
Levy SC, Freed DJ, Nilsson M, Moore BCJ, Puria S (2015) Extended high-frequency bandwidth improves speech reception in the presence of spatially separated masking speech. Ear Hear 36:e214–e224. https://doi.org/10.1097/AUD.0000000000000161
doi: 10.1097/AUD.0000000000000161
pubmed: 25856543
pmcid: 4549240
Van Eeckhoutte M, Scollie S, O’Hagan R, Glista D (2020) Perceptual benefits of extended bandwidth hearing aids with children: a within-subject design using clinically available hearing aids. J Speech Lang Hear Res 63:3834–3846. https://doi.org/10.1044/2020_JSLHR-20-00271
doi: 10.1044/2020_JSLHR-20-00271
pubmed: 33002368
Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Grégoire V, Van Herk M, Lee A, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA (2015) CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG oncology and TROG consensus guidelines. Radiother Oncol 117:83–90. https://doi.org/10.1016/j.radonc.2015.07.041
doi: 10.1016/j.radonc.2015.07.041
pubmed: 26277855
Van Linge A, Van Os R, Hoekstra N, Heijmen B, Stienstra L, Dallenga A, Wolbers J, Mendez Romero A (2018) Progression of hearing loss after LINAC-based stereotactic radiotherapy for vestibular schwannoma is associated with cochlear dose, not with pre-treatment hearing level. Radiat Oncol 13:1–12. https://doi.org/10.1186/s13014-018-1202-z
doi: 10.1186/s13014-018-1202-z
Lamaj E, Vu E, van Timmeren JE, Leonardi C, Marc L, Pytko I, Guckenberger M, Balermpas P (2021) Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. Radiat Oncol 16:1–12. https://doi.org/10.1186/s13014-021-01796-4
doi: 10.1186/s13014-021-01796-4
Honoré HB, Bentzen SM, Møller K, Grau C (2002) Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: Individualized risk estimation. Radiother Oncol 65:9–16. https://doi.org/10.1016/S0167-8140(02)00173-1
doi: 10.1016/S0167-8140(02)00173-1
pubmed: 12413669
Hoppe U, Hast A, Hocke T (2015) Audiometry-based screening procedure for cochlear implant candidacy. Otol Neurotol 36:1001–1005. https://doi.org/10.1097/MAO.0000000000000730
doi: 10.1097/MAO.0000000000000730
pubmed: 25700016
Hoppe U, Hocke T, Hast A, Hornung J (2017) Langzeitergebnisse eines Screeningverfahrens für erwachsene Longterm Results of a Screening Procedure for Adult Cochlear Implant Candidates. Einleit Method: 234–238
Leigh JR, Dettman SJ, Dowell RC (2016) Evidence-based guidelines for recommending cochlear implantation for young children: audiological criteria and optimizing age at implantation. Int J Audiol 55:S9–S18. https://doi.org/10.3109/14992027.2016.1157268
doi: 10.3109/14992027.2016.1157268
pubmed: 27142630
Aschendorff A, Baumann U, Delank K‑W, Ernst A, Hoppe U, Hupka O, Keppner S, Klenzner T, Lailach S, Langer J, Lenarz T, Mlynski R, Müller J, Mürbe D, Schmidt F, Seidler H, Stöver T, Streicher B, Struffert T, Wachtlin B, Zahnert T, Zeh R (2020) S2k-Leitlinie Cochlea-Implantat Versorgung
Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR (2005) Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61:1393–1402. https://doi.org/10.1016/j.ijrobp.2004.08.019
doi: 10.1016/j.ijrobp.2004.08.019
pubmed: 15817342
Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC (2009) Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 73:779–788. https://doi.org/10.1016/j.ijrobp.2008.05.040
doi: 10.1016/j.ijrobp.2008.05.040
pubmed: 18707819
Petsuksiri J, Sermsree A, Thephamongkhol K, Keskool P, Thongyai K, Chansilpa Y, Pattaranutaporn P (2011) Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. Radiat Oncol 6:19. https://doi.org/10.1186/1748-717X-6-19
doi: 10.1186/1748-717X-6-19
pubmed: 21333025
pmcid: 3048471
Gupta T, Mohanty S, Kannan S, Jalali R (2014) Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma. Neurooncol Pract 1:86–93. https://doi.org/10.1093/nop/npu017
doi: 10.1093/nop/npu017
pubmed: 31386031
pmcid: 6657387
Merchant TE, Gould CJ, Xiong X, Robbins N, Zhu J, Pritchard DL, Khan R, Heideman RL, Krasin MJ, Kun LE (2004) Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys 58:1194–1207. https://doi.org/10.1016/j.ijrobp.2003.07.008
doi: 10.1016/j.ijrobp.2003.07.008
pubmed: 15001264
Cohen-Cutler S, Wong K, Mena V, Sianto K, Wright MA, Olch A, Orgel E (2021) Hearing loss risk in pediatric patients treated with cranial irradiation and Cisplatin-based chemotherapy. Int J Radiat Oncol Biol Phys 110:1488–1495. https://doi.org/10.1016/j.ijrobp.2021.02.050
doi: 10.1016/j.ijrobp.2021.02.050
pubmed: 33677052
pmcid: 8286302
Khong J, Govindaraj R, Ramm D, Edwards S, Roos D (2023) Cochlear sparing in LINAC-based radiosurgery for vestibular schwannoma: a dosimetric comparison of dynamic conformal arc, IMRT and VMAT treatment plans. Radiat Oncol 18:1–7. https://doi.org/10.1186/s13014-022-02188-y
doi: 10.1186/s13014-022-02188-y
Pichandi A, Ganesh KM, Jerrin A, Balaji K, Sridhar PS, Surega A (2015) Cranio spinal irradiation of medulloblastoma using high precision techniques—A dosimetric comparison. Technol Cancer Res Treat 14:491–496. https://doi.org/10.1177/1533034614500421
doi: 10.1177/1533034614500421
pubmed: 26269611
Breen WG, Geno CS, Waddle MR, Qian J, Harmsen WS, Burns TC, Sener UT, Ruff MW, Neth BJ, Uhm JH, Routman DM, Yan E, Kruse JJ, Laack NN, Brown PD, Mahajan A (2024) Proton versus photon craniospinal irradiation for adult medulloblastoma: a dosimetric, toxicity, and exploratory cost analysis. Neurooncol Adv 6:1–7. https://doi.org/10.1093/noajnl/vdae034
doi: 10.1093/noajnl/vdae034
Paulino AC, Mahajan A, Ye R, Grosshans DR, Fatih Okcu M, Su J, McAleer MF, McGovern S, Mangona VA, Chintagumpala M (2018) Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol 128:128–132. https://doi.org/10.1016/j.radonc.2018.01.002
doi: 10.1016/j.radonc.2018.01.002
pubmed: 29373195
Fukumitsu N, Kubota H, Mima M, Demizu Y, Suzuki T, Hasegawa D, Kosaka Y, Kawamura A, Soejima T (2023) Comparison of craniospinal irradiation using proton beams according to irradiation method and initial experience treating pediatric patients. Adv Radiat Oncol 8:101251. https://doi.org/10.1016/j.adro.2023.101251
doi: 10.1016/j.adro.2023.101251
pubmed: 37408669
pmcid: 10318217
von Hoff K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N, Zwiener I, Goette H, Schlegel PG, Pietsch T, Kortmann RD, Kuehl J, Rutkowski S (2009) Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT’91. Eur J Cancer 45:1209–1217. https://doi.org/10.1016/j.ejca.2009.01.015
doi: 10.1016/j.ejca.2009.01.015
pubmed: 19250820
Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J (1991) Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295–300. https://doi.org/10.1002/mpo.2950190415
doi: 10.1002/mpo.2950190415
pubmed: 2056973
Tarbell NJ, Smith AR, Adams J, Loeffler JS (2000) The challenge of conformal radiotherapy in the curative treatment of medulloblastoma. Int J Radiat Oncol Biol Phys 46:265–266. https://doi.org/10.1016/S0360-3016(99)00366-1
doi: 10.1016/S0360-3016(99)00366-1
pubmed: 10661330
Pacholke HD, Amdur RJ, Schmalfuss IM, Louis D, Mendenhall WM (2005) Contouring the middle and inner ear on radiotherapy planning scans. Am J Clin Oncol Cancer Clin Trials 28:143–147. https://doi.org/10.1097/01.coc.0000143847.57027.16
doi: 10.1097/01.coc.0000143847.57027.16
Nguyen NP, Smith-Raymond L, Vinh-Hung V, Sloan D, Davis R, Vos P, Abraham D, Stevie M, Krafft SP, Ly BH, Ries T, Karlsson U, Ceizyk M (2011) Feasibility of tomotherapy to spare the cochlea from excessive radiation in head and neck cancer. Oral Oncol 47:414–419. https://doi.org/10.1016/j.oraloncology.2011.03.011
doi: 10.1016/j.oraloncology.2011.03.011
pubmed: 21474364
Guimas V, Thariat J, Graff-Cailleau P, Boisselier P, Pointreau Y, Pommier P, Montbarbon X, Laude C, Racadot S (2016) Radiothérapie conformationnelle avec modulation d’intensité des cancers des voies aérodigestives supérieures, dose de tolérance des tissus sains : appareil cochléovestibulaire et tronc cérébral. Cancer Radiother 20:475–483. https://doi.org/10.1016/j.canrad.2016.07.077
doi: 10.1016/j.canrad.2016.07.077
pubmed: 27614519
Oh YT, Kim CH, Choi JH, Kang SH, Chun M (2004) Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol 72:79–82. https://doi.org/10.1016/j.radonc.2004.02.009
doi: 10.1016/j.radonc.2004.02.009
pubmed: 15236878
Kretschmar CS, Warren MP, Lavally BL, Dyer S, Tarbell NJ (1990) Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol 8:1191–1198. https://doi.org/10.1200/JCO.1990.8.7.1191
doi: 10.1200/JCO.1990.8.7.1191
pubmed: 2358836
Beyea JA, Lau C, Cooke B, Hall S, Nathan PC, Gupta S (2020) Long-term incidence and predictors of significant hearing loss requiring hearing assistive devices among childhood cancer survivors: A population-based study. J Clin Oncol 38:2639–2646. https://doi.org/10.1200/JCO.19.03166
doi: 10.1200/JCO.19.03166
pubmed: 32463737
Kwong DL, Wei WI, Sham JS, Ho WK, Yuen PW, Chua DT, Au DK, Wu PM, Choy DT (1996) Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys 36:281–289. https://doi.org/10.1016/s0360-3016(96)00302-1
doi: 10.1016/s0360-3016(96)00302-1
pubmed: 8892450
Wei Y, Zhou T, Zhu J, Zhang Y, Sun M, Ding X, Wang D, Li H, Li B (2014) Long-term outcome of sensorineural hearing loss in nasopharyngeal carcinoma patients: comparison between treatment with radiotherapy alone and Chemoradiotherapy. Cell Biochem Biophys 69:433–437. https://doi.org/10.1007/s12013-014-9814-x
doi: 10.1007/s12013-014-9814-x
pubmed: 24510513
Ho WK, Wei WI, Kwong DLW, Sham JST, Tai PTH, Yuen APW, Au DKK (1999) Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck 21:547–553
doi: 10.1002/(SICI)1097-0347(199909)21:6<547::AID-HED8>3.0.CO;2-Y
pubmed: 10449671
Murphy B, Jackson A, Bass JK, Tsang DS, Ronckers CM, Kremer L, Baliga S, Olch A, Zureick AH, Jee KW, Constine LS, Yock TI (2024) Modeling the risk of hearing loss from radiation therapy in childhood cancer survivors: a PENTEC comprehensive review. Int J Radiat Oncol Biol Phys 119:446–456. https://doi.org/10.1016/j.ijrobp.2023.08.016
doi: 10.1016/j.ijrobp.2023.08.016
pubmed: 37855793
Walker DA, Pillow J, Waters KD, Keir E (1989) Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol 17:48–52. https://doi.org/10.1002/mpo.2950170110
doi: 10.1002/mpo.2950170110
pubmed: 2913475
Sun W, Wang W (2015) Advances in research on labyrinth membranous barriers. J Otol 10:99–104. https://doi.org/10.1016/j.joto.2015.11.003
doi: 10.1016/j.joto.2015.11.003
pubmed: 29937790
pmcid: 6002577